Does Affinity Health Plan Cover Ozempic?

Affinity Health Plan No Longer Exists as a Standalone Insurer

Affinity Health Plan was a nonprofit Medicaid managed care organization based in the Bronx, New York, serving members across New York City and surrounding counties. In 2014, Molina Healthcare completed its acquisition of Affinity Health Plan, absorbing all of its approximately 275,000 members into the Molina Healthcare of New York network.

What This Means for Former Affinity Members

If you originally enrolled through Affinity Health Plan, your benefits, formulary, and provider network are now governed by Molina Healthcare of New York. Your member ID card, plan documents, and pharmacy benefits all fall under Molina's administration. Any search for "Affinity Health Plan formulary" should redirect to Molina's current drug list.

How to Verify Your Current Plan

Call the number on the back of your insurance card or visit Molina Healthcare's member portal. New York State's Medicaid managed care enrollment page can also confirm which plan you belong to. If you have been auto-assigned to a different managed care organization during annual enrollment periods, your GLP-1 coverage terms may differ from what Molina offers.

Ozempic Coverage Under Molina Healthcare of New York (Medicaid)

Molina Healthcare of New York includes Ozempic on its Medicaid managed care formulary for the treatment of type 2 diabetes mellitus. The drug is classified as a non-preferred brand, which means prior authorization is required before the pharmacy can fill the prescription.

Prior Authorization Requirements

Molina's prior authorization criteria for Ozempic generally follow New York State Medicaid's clinical guidelines. Prescribers must document that the patient has a confirmed diagnosis of type 2 diabetes, a recent A1C at or above 7%, and has tried or has a contraindication to metformin as first-line therapy. The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line agents when metformin alone fails to achieve glycemic targets [1].

Step Therapy Protocols

Step therapy is common across Medicaid managed care plans. Molina may require evidence that one or more preferred GLP-1 agents (such as dulaglutide or liraglutide) were tried before approving Ozempic specifically. This is a cost-containment measure, not a clinical judgment about Ozempic's efficacy. In the SUSTAIN-7 trial (N=1,201), semaglutide 0.5 mg and 1 mg demonstrated superior A1C reduction compared to dulaglutide 0.75 mg and 1.5 mg at 40 weeks, with mean A1C reductions of 1.5% and 1.8% respectively versus 1.1% and 1.4% for dulaglutide [2].

Typical Approval Timelines

Standard prior authorization decisions take 24 to 72 hours. Urgent requests can be processed in under 24 hours. If denied, you have the right to a fair hearing through New York State's Medicaid appeals process.

What Ozempic Costs Without Insurance in New York

Ozempic's wholesale acquisition cost is approximately $935.77 for a single 1 mg/dose pen (four weekly injections). Without any coverage, retail pharmacy prices in New York range from $900 to $1,100 per month depending on the pharmacy and dosage strength.

Manufacturer Savings Programs

Novo Nordisk offers a savings card that can reduce out-of-pocket costs to as little as $25 per fill for commercially insured patients. This program does not apply to Medicaid, Medicare, or other government-funded plans. Medicaid recipients who receive Ozempic through a covered formulary typically pay $0 to $3 per prescription at the pharmacy, depending on the plan's copay structure.

Patient Assistance for the Uninsured

Novo Nordisk's Patient Assistance Program (PAP) provides free Ozempic to qualifying uninsured patients with household income at or below 400% of the federal poverty level. The application requires income verification and a prescription from a licensed provider.

The Clinical Case for Ozempic in Type 2 Diabetes

Ozempic (semaglutide) is a once-weekly GLP-1 receptor agonist approved by the FDA in December 2017 for improving glycemic control in adults with type 2 diabetes. It is not FDA-approved for weight management (that indication belongs to Wegovy, the 2.4 mg formulation of semaglutide).

Efficacy Data From the SUSTAIN Program

The SUSTAIN clinical trial program enrolled over 8,000 patients across multiple phase 3 studies. In SUSTAIN-6 (N=3,297), semaglutide reduced the risk of major adverse cardiovascular events (MACE) by 26% compared to placebo over a median follow-up of 2.1 years (HR 0.74, 95% CI 0.58-0.95, P=0.016) [3]. This cardiovascular benefit is one reason the ADA guidelines specifically recommend GLP-1 receptor agonists for patients with type 2 diabetes and established cardiovascular disease.

How Ozempic Compares to Other Covered GLP-1s

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "The GLP-1 receptor agonist class has become a cornerstone of type 2 diabetes management, but individual agents differ meaningfully in A1C lowering, weight effects, and cardiovascular outcomes data" [4]. Among injectable GLP-1 receptor agonists, semaglutide has consistently shown the largest A1C reductions in head-to-head trials. The SUSTAIN-10 trial (N=577) found semaglutide 1 mg reduced A1C by 1.7 percentage points versus 1.0 for liraglutide 1.2 mg at 30 weeks [5].

Weight Loss as a Secondary Benefit

While Ozempic is prescribed for glucose control, weight reduction is a well-documented secondary effect. Across the SUSTAIN program, patients on semaglutide 1 mg lost an average of 4.5 to 6.5 kg over 30 to 56 weeks [6]. This weight reduction contributes to improved insulin sensitivity and may reduce the need for additional diabetes medications over time.

New York Medicaid and GLP-1 Coverage: The Broader Picture

New York's Medicaid program is one of the largest in the United States, covering over 7 million enrollees. The state's Medicaid Drug Utilization Review Board evaluates GLP-1 receptor agonists for inclusion on the preferred drug list.

Which GLP-1 Agents Are Preferred in New York Medicaid?

Preferred status changes periodically based on supplemental rebate agreements between the state and manufacturers. As of 2025, dulaglutide (Trulicity) and liraglutide (Victoza) have held preferred positions on several New York Medicaid managed care formularies. Ozempic remains accessible but often requires the additional step of prior authorization.

Coverage for Weight Management Versus Diabetes

New York Medicaid began covering anti-obesity medications for qualifying enrollees in 2024, following guidance from CMS. Coverage for weight management typically requires a BMI of 30 or higher (or 27 with a weight-related comorbidity) and documentation of lifestyle modification attempts. Wegovy, not Ozempic, is the appropriate semaglutide product for this indication. The 2022 ADA/AACE consensus statement emphasized that "pharmacotherapy for obesity should be considered for patients with BMI ≥27 kg/m² and at least one weight-related complication" [7].

The Difference Between Ozempic and Wegovy for Coverage Purposes

Ozempic and Wegovy contain the same active molecule (semaglutide) but carry different FDA approvals, different NDC numbers, and different formulary placements. Prescribing Ozempic for weight loss is off-label and will almost certainly be denied by Medicaid. Prescribing Wegovy for weight management, with the correct diagnosis codes, follows the FDA-approved indication and is more likely to receive coverage approval.

How to Get Ozempic Approved Through Your Plan

The prior authorization process can feel opaque, but there are concrete steps that increase approval rates.

Step 1: Confirm Your Diagnosis and Labs

Your prescriber needs to submit documentation showing a type 2 diabetes diagnosis (ICD-10 code E11.xx), a recent A1C result at or above 7%, and evidence of prior metformin use or a documented reason metformin cannot be used (such as GFR <30 mL/min/1.73 m² or gastrointestinal intolerance). Lab work should be dated within the past 90 days.

Step 2: Let Your Prescriber Handle the PA

Most prior authorization forms can be submitted electronically through the pharmacy benefit manager's portal. The prescriber's office fills out the clinical questionnaire, attaches lab results, and submits within the same day. Molina's pharmacy team reviews the request against their formulary criteria.

Step 3: Know Your Appeal Rights

If the PA is denied, New York State law guarantees you the right to an internal appeal through Molina and, if that fails, an external review through the New York State Department of Financial Services. Medicaid recipients can also request a fair hearing through the Office of Temporary and Disability Assistance. In 2023, approximately 40-60% of GLP-1 prior authorization denials were overturned on appeal when additional clinical documentation was submitted [8].

Side Effects and Monitoring on Ozempic

Ozempic's side effect profile is well-characterized across over 10,000 patients studied in clinical trials. The most common adverse events are gastrointestinal: nausea (15-20%), diarrhea (8-9%), vomiting (5-9%), and constipation (3-5%) according to the FDA prescribing information [9].

GI Side Effects and Dose Titration

Slow dose titration reduces GI symptoms significantly. The standard protocol starts at 0.25 mg weekly for four weeks (a sub-therapeutic dose intended solely for GI acclimation), then increases to 0.5 mg for at least four weeks before considering the 1 mg dose. Rushing this schedule is the most common cause of early discontinuation.

Serious but Rare Risks

Ozempic carries a boxed warning for thyroid C-cell tumors based on rodent studies. In humans, this risk has not been confirmed, but the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Pancreatitis has been reported at rates slightly above background in GLP-1 receptor agonist trials, and prescribers should monitor for persistent severe abdominal pain [10].

Monitoring Schedule

Baseline labs before starting Ozempic should include A1C, fasting glucose, a comprehensive metabolic panel (including renal function), lipid panel, and thyroid function. A1C should be rechecked at 3 months to assess initial response. If A1C has not dropped by at least 0.5 percentage points, the dose should be increased or the regimen reconsidered. The ADA Standards of Care recommend A1C testing every 3 to 6 months for patients on stable therapy [11].

Alternatives if Ozempic Is Denied

If Ozempic is not approved through your Molina (formerly Affinity) plan, several alternatives remain within the GLP-1 class.

Preferred GLP-1 Alternatives

Dulaglutide (Trulicity) is dosed once weekly and produced A1C reductions of 0.78% to 1.64% across the AWARD trial program depending on dose and comparator [12]. Liraglutide (Victoza) requires daily injection but has strong cardiovascular outcomes data from the LEADER trial (N=9,340), which showed a 13% reduction in MACE versus placebo over 3.8 years (HR 0.87, 95% CI 0.78-0.97, P=0.01) [13].

Oral Semaglutide

Rybelsus (oral semaglutide, 7 mg and 14 mg tablets) contains the same active molecule as Ozempic in pill form. In the PIONEER-4 trial (N=711), oral semaglutide 14 mg reduced A1C by 1.2 percentage points at 52 weeks, comparable to subcutaneous liraglutide 1.8 mg [14]. Some Medicaid formularies may cover oral semaglutide with a different prior authorization pathway than the injectable formulation.

Non-GLP-1 Options

If GLP-1 agents are inaccessible, SGLT2 inhibitors such as empagliflozin and dapagliflozin offer A1C reductions of 0.5-0.8% with added cardiovascular and renal protection benefits. Pioglitazone remains a low-cost option (under $15/month generic) for patients who need additional glucose lowering beyond metformin.

Patients whose A1C remains above 9% despite oral therapy should discuss insulin initiation with their provider, as the ADA recommends considering insulin when A1C exceeds 10% or when symptoms of hyperglycemia are present [11].